Deutsch English Français

Contact

EP3240801

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...

Extract from the Register of European Patents

EP About this file: EP3240801

EP3240801 - COMBINATION TUMOR IMMUNOTHERAPY [Right-click to bookmark this link]
Status	No opposition filed within time limit Status updated on 26.11.2021 Database last updated on 08.04.2026
Former	The patent has been granted Status updated on 18.12.2020
Former	Grant of patent is intended Status updated on 02.11.2020
Former	Examination is in progress Status updated on 05.06.2019
Former	Request for examination was made Status updated on 06.10.2017
Former	The international publication has been made Status updated on 23.06.2017
Most recent event Tooltip	26.11.2021	No opposition filed within time limit	published on 29.12.2021 [2021/52]
Applicant(s)	For all designated states Checkmate Pharmaceuticals, Inc. 1 Broadway, 14th Floor Cambridge, MA 02142 / US
	[2021/03]
Former [2017/45]	For all designated states Checkmate Pharmaceuticals, Inc. 1 Broadway, 14th Floor Cambridge MA 02142 / US
Inventor(s)	01 / KRIEG, Arthur, M. 49 Trowbridge Street Unit 3 Cambridge, MA 02138 / US
	[2017/45]
Representative(s)	Gill, Siân Victoria Venner Shipley LLP 200 Aldersgate London EC1A 4HD / GB
	[2021/03]
Former [2017/45]	Jump, Timothy John Simon, et al Venner Shipley LLP 200 Aldersgate London EC1A 4HD / GB
Application number, filing date	15876030.6	22.12.2015
	[2017/45]
	WO2015US67269
Priority number, date	US201462098568P	31.12.2014 Original published format: US 201462098568 P
	US201562106526P	22.01.2015 Original published format: US 201562106526 P
	US201562118165P	19.02.2015 Original published format: US 201562118165 P
	[2017/45]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO2016109310
	Date:	07.07.2016
	Language:	EN
	[2016/27]
	Type:	A1 Application with search report
	No.:	EP3240801
	Date:	08.11.2017
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 07.07.2016 takes the place of the publication of the European patent application.
	[2017/45]
	Type:	B1 Patent specification
	No.:	EP3240801
	Date:	20.01.2021
	Language:	EN
	[2021/03]
Search report(s)	International search report - published on:	US	07.07.2016
	(Supplementary) European search report - dispatched on:	EP	26.06.2018
Classification	IPC:	A61K31/7125, C07K14/56, A61P35/00, C07K16/28	[2020/48]
	CPC:	A61K31/7125 (EP,US); A61K31/70 (US); A61K31/713 (EP,US); A61K39/39541 (EP,US); A61K45/06 (EP,US); A61P35/00 (EP,US); (+) C07K16/104 (EP,US); C07K16/2818 (EP,US); C12N15/117 (EP,US); A61K2039/505 (EP,US); A61K39/00 (EP,US); C12N2310/17 (EP,US); C12N2320/31 (EP,US) (-)
	C-Set:	A61K31/713, A61K2300/00 (US,EP); A61K39/39541, A61K2300/00 (EP,US)
	Former IPC [2018/30]	C07K14/56, A61P35/00, C07K16/28
	Former IPC [2017/45]	C07K14/56
Designated contracting states	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2017/45]
Extension states	BA	Not yet paid
	ME	Not yet paid
Validation states	MA	Not yet paid
	MD	Not yet paid
Title	German:	KOMBINATIONSTUMORIMMUNTHERAPIE	[2017/45]
	English:	COMBINATION TUMOR IMMUNOTHERAPY	[2017/45]
	French:	IMMUNOTHÉRAPIE ANTI-TUMORALE COMBINÉE	[2017/45]
Entry into regional phase	23.06.2017	National basic fee paid
	23.06.2017	Search fee paid
	23.06.2017	Designation fee(s) paid
	23.06.2017	Examination fee paid
Examination procedure	23.06.2017	Examination requested [2017/45]
	23.06.2017	Date on which the examining division has become responsible
	22.01.2019	Amendment by applicant (claims and/or description)
	11.06.2019	Despatch of a communication from the examining division (Time limit: M06)
	17.12.2019	Reply to a communication from the examining division
	20.10.2020	Cancellation of oral proceeding that was planned for 09.11.2020
	03.11.2020	Communication of intention to grant the patent
	09.11.2020	Date of oral proceedings (cancelled)
	15.12.2020	Fee for grant paid
	15.12.2020	Fee for publishing/printing paid
	15.12.2020	Receipt of the translation of the claim(s)
Divisional application(s)	EP21151085.4 / EP3835312
Opposition(s)	21.10.2021	No opposition filed within time limit [2021/52]
Fees paid	Renewal fee
	28.12.2017	Renewal fee patent year 03
	12.12.2018	Renewal fee patent year 04
	13.12.2019	Renewal fee patent year 05
	14.12.2020	Renewal fee patent year 06
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:	Search	[XI] WO2012006634 (TRUSTEES OF THE UNIVERSITY OF ILLINIOIS BOARD OF et al.) [X] 1-13 * examples 1-2; claims 16-21 *[I] 14,15
		[Y] WO03024481 (CYTOS BIOTECHNOLOGY AG et al.) [Y] 14,15 * claims 21,92 *
		[XYI] MANGSBO SARA M ET AL: "Enhanced Tumor Eradication by Combining CTLA-4 or PD-1 Blockade With CpG Therapy", JOURNAL OF IMMUNOTHERAPY, LIPPINCOTT WILLIAMS & WILKINS, US, vol. 33, no. 3, 1 April 2010 (2010-04-01), pages 225 - 235, XP009144370, ISSN: 1524-9557 [X] 1,3-12 * the whole document *[Y] 2,14,15 [I] 13
		[Y] STEFAN NIERKENS ET AL: "Route of Administration of the TLR9 Agonist CpG Critically Determines the Efficacy of Cancer Immunotherapy in Mice", PLOS ONE, vol. 4, no. 12, 1 January 2009 (2009-01-01), pages e8368 - e8368, XP055042111, ISSN: 1932-6203, DOI: 10.1371/journal.pone.0008368 [Y] 2 * abstract * DOI: http://dx.doi.org/10.1371/journal.pone.0008368
		[I] WONG R M ET AL: "TLR-9 signaling and TCR stimulation co-regulate CD8+ T cell-associated PD-1 expression", IMMUNOLOGY LETTERS, ELSEVIER BV, NL, vol. 127, no. 1, 2 December 2009 (2009-12-02), pages 60 - 67, XP026745618, ISSN: 0165-2478, [retrieved on 20090912], DOI: 10.1016/J.IMLET.2009.09.002 [I] 1-15 * page 64, column l - column r; figure 6 * DOI: http://dx.doi.org/10.1016/j.imlet.2009.09.002
		[T] LEMKE CAITLIN D ET AL: "Combination Lymphoma Immunotherapy Using Checkpoint Blockade and Intratumoral Virus-like Particles Containing CpG TLR9 Agonist - Abstract 3023", BLOOD, & 58TH ANNUAL MEETING AND EXPOSITION OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY; SAN DIEGO, CA, USA; DECEMBER 03 -06, 2016, vol. 128, no. 22, 2 December 2016 (2016-12-02), XP002771299 [T] * the whole document *
		[A] QI XU-FENG ET AL: "CpG oligodeoxynucleotide induces apoptosis and cell cycle arrest in A20 lymphoma cells via TLR9-mediated pathways", MOLECULAR IMMUNOLOGY, PERGAMON, GB, vol. 54, no. 3, 26 January 2013 (2013-01-26), pages 327 - 337, XP028998721, ISSN: 0161-5890, DOI: 10.1016/J.MOLIMM.2013.01.001 [A] 1-15 * the whole document * DOI: http://dx.doi.org/10.1016/j.molimm.2013.01.001
		[A] KIM Y H ET AL: "Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma", JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, MOSBY, INC, US, vol. 63, no. 6, 1 December 2010 (2010-12-01), pages 975 - 983, XP027499048, ISSN: 0190-9622, [retrieved on 20101118], DOI: 10.1016/J.JAAD.2009.12.052 [A] 1-15 * abstract * DOI: http://dx.doi.org/10.1016/j.jaad.2009.12.052
		[A] ASSAF A ET AL: "A threshold level of TLR9 mRNA predicts cellular responsiveness to CpG-ODN in haematological and non-haematological tumour cell lines", CELLULAR IMMUNOLOGY, ACADEMIC PRESS, SAN DIEGO, CA, US, vol. 259, no. 1, 1 January 2009 (2009-01-01), pages 90 - 99, XP026459070, ISSN: 0008-8749, [retrieved on 20090606] [A] 1-15 * the whole document *
		[A] MASON K A ET AL: "Molecular targeting of toll-like receptor 9 with CpG oligodeoxynucleotides (ODN) for enhancement of tumor radioresponse", INTERNATIONAL JOURNAL OF RADIATION: ONCOLOGY BIOLOGY PHYS, PERGAMON PRESS, USA, vol. 60, no. 1, 1 September 2004 (2004-09-01), pages S346, XP004557674, ISSN: 0360-3016 [A] 1-15 * abstract *
	International search	[XY] US2012251494 (KEDL ROSS et al.) [X] 1-3, 25-27, 49-51 * entire document *[Y] 28
		[A] US2009082295 (JUNGNELIUS JARL ULF BIRGER et al.) [A] 1-3, 25-28, 49-51 * entire document *
		[Y] KRUG ET AL.: "Identification of CpG oligonucleotide sequences with high induction of IFN-aip in plasmacytoid dendritic cells''.", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 31, no. 7, 1 July 2001 (2001-07-01), pages 2154 - 2163, XP002292085 [Y] 28 * entire document * DOI: http://dx.doi.org/10.1002/1521-4141(200107)31:7<2154::AID-IMMU2154>3.0.CO;2-U
		[A] BUTT ET AL.: "Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines''.", ONCOGENE, vol. 1, no. 9, 21 October 2013 (2013-10-21) [A] 1-3, 25-28, 49-51 * entire document *
		[A] KORTYLEWSKI ET AL.: "In vivo delivery of sirNA to immune cells by conjugation to a tlr9 agonist enhances antitumor immune responses''.", NATURE BIOTECHNOLOGY, vol. 27, no. 10, October 2009 (2009-10-01), pages 925, XP055460942 [A] 1-3, 25-28, 49-51 * entire document * DOI: http://dx.doi.org/10.1038/nbt.1564
	Examination	HARTMANN EVELYN ET AL: "Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer.", CANCER RESEARCH 01 OCT 2003, vol. 63, no. 19, 1 October 2003 (2003-10-01), pages 6478 - 6487, ISSN: 0008-5472 [X] 1,3-12 * the whole document *[Y] 2,14,15 [I] 13
		LABIDI-GALY SANA INTIDHAR ET AL: "Quantitative and functional alterations of plasmacytoid dendritic cells contribute to immune tolerance in ovarian cancer.", CANCER RESEARCH 15 AUG 2011, vol. 71, no. 16, 15 August 2011 (2011-08-15), pages 5423 - 5434, ISSN: 1538-7445 [I] 14,15
		SISIRAK VANJA ET AL: "Impaired IFN-[alpha] production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progression.", CANCER RESEARCH 15 OCT 2012, vol. 72, no. 20, 15 October 2012 (2012-10-15), pages 5188 - 5197, ISSN: 1538-7445 [Y] 2 * abstract *
		ZOU W ET AL: "Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells.", NATURE MEDICINE DEC 2001, vol. 7, no. 12, December 2001 (2001-12-01), pages 1339 - 1346, ISSN: 1078-8956
		WATKINS STEPHANIE K ET AL: "FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer.", THE JOURNAL OF CLINICAL INVESTIGATION APR 2011, vol. 121, no. 4, April 2011 (2011-04-01), pages 1361 - 1372, ISSN: 1558-8238 [I] 1-15 * page 64, column l - column r; figure 6 *
		CONRAD CURDIN ET AL: "Plasmacytoid dendritic cells promote immunosuppression in ovarian cancer via ICOS costimulation of Foxp3(+) T-regulatory cells.", CANCER RESEARCH 15 OCT 2012, vol. 72, no. 20, 15 October 2012 (2012-10-15), pages 5240 - 5249, ISSN: 1538-7445 [T] * the whole document *
		FAGET JULIEN ET AL: "ICOS-ligand expression on plasmacytoid dendritic cells supports breast cancer progression by promoting the accumulation of immunosuppressive CD4+ T cells.", CANCER RESEARCH 01 DEC 2012, vol. 72, no. 23, 1 December 2012 (2012-12-01), pages 6130 - 6141, ISSN: 1538-7445 [A] 1-15 * the whole document *
		KRUG A ET AL: "Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells.", EUROPEAN JOURNAL OF IMMUNOLOGY JUL 2001, vol. 31, no. 7, July 2001 (2001-07-01), pages 2154 - 2163, ISSN: 0014-2980 [A] 1-15 * abstract *
		BATES P J ET AL: "Antiproliferative activity of G-rich oligonucleotides correlates with protein binding.", THE JOURNAL OF BIOLOGICAL CHEMISTRY 10 SEP 1999, vol. 274, no. 37, 10 September 1999 (1999-09-10), pages 26369 - 26377, ISSN: 0021-9258 [A] 1-15 * the whole document *
		SHEN WEIYIN ET AL: "Antitumor mechanisms of oligodeoxynucleotides with CpG and polyG motifs in murine prostate cancer cells: decrease of NF-kappaB and AP-1 binding activities and induction of apoptosis.", ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT JUN 2002, vol. 12, no. 3, June 2002 (2002-06-01), pages 155 - 164, ISSN: 1087-2906 [A] 1-15 * abstract *
		ROTHENFUSSER SIMON ET AL: "CpG-A and CpG-B oligonucleotides differentially enhance human peptide-specific primary and memory CD8+ T-cell responses in vitro.", BLOOD 15 MAR 2004, vol. 103, no. 6, 15 March 2004 (2004-03-15), pages 2162 - 2169, ISSN: 0006-4971
		KATSUDA MASAHIRO ET AL: "Comparison of different classes of CpG-ODN in augmenting the generation of human epitope peptide-specific CTLs.", INTERNATIONAL JOURNAL OF ONCOLOGY NOV 2011, vol. 39, no. 5, November 2011 (2011-11-01), pages 1295 - 1302, ISSN: 1791-2423
		PENG GUANGYONG ET AL: "Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function.", SCIENCE (NEW YORK, N.Y.) 26 AUG 2005, vol. 309, no. 5739, 26 August 2005 (2005-08-26), pages 1380 - 1384, ISSN: 1095-9203
		HONDA KENYA ET AL: "Spatiotemporal regulation of MyD88-IRF-7 signalling for robust type-I interferon induction.", NATURE 21 APR 2005, vol. 434, no. 7036, 21 April 2005 (2005-04-21), pages 1035 - 1040, ISSN: 1476-4687
		GUIDUCCI CRISTIANA ET AL: "Properties regulating the nature of the plasmacytoid dendritic cell response to Toll-like receptor 9 activation.", THE JOURNAL OF EXPERIMENTAL MEDICINE 07 AUG 2006, vol. 203, no. 8, 7 August 2006 (2006-08-07), pages 1999 - 2008, ISSN: 0022-1007
		CHAN MEI PO ET AL: "DNase II-dependent DNA digestion is required for DNA sensing by TLR9.", NATURE COMMUNICATIONS 20 JAN 2015, vol. 6, 20 January 2015 (2015-01-20), pages 5853, ISSN: 2041-1723
		ALCULUMBRE SOLANA G ET AL: "Diversification of human plasmacytoid predendritic cells in response to a single stimulus.", NATURE IMMUNOLOGY JAN 2018, vol. 19, no. 1, January 2018 (2018-01-01), pages 63 - 75, ISSN: 1529-2916
	by applicant	WO2012006634
		US5922845
		US5837243
		US8017591
		US7635468
		US7074772
		US6849725
		US6451593
		US6451563
		US2003125279
		US9501570
		US9719791
		US6194388
		US6239116
		US6949520
		US7776344
		WO03024481
		US2003099668
		US2012301499
		WO2004084940
		US7517520
		US2010098722
		WO2007068747
		US2007184068
		US8574564
		WO2007144150
		US8541559
		WO2008073960
		US8586728
		US7566703
		US8198251
		US8834900
		US2008045473
		US8580268
		US2014163213
		US4469863
		US5023243
		EP0092574
		US7795235
		US8283328
		US8304396
		US5177198
		US5859231
		US6160109
		US6207819
		US9917100
		WO0006588
		WO9501363
		US5658738
		US5668265
		US6808710
		US7488802
		US8728474
		US7943743
		US9930895
		WO0037504
		EP1262193
		US47208799
		US6682736
		US94893901
		US2002086014
		US98839609
		US2009117132
		US201113168206
	US2012003179
	US2003086930
	US2002088014
	US5770429
	US2004120948
	US5703057
	US4816567
	EP0216846
	EP0256055
	EP0323997
	EP89303964
	US2003207336
	US2003157108
	WO0181405
	WO0024893
	WO03031464
	WO9858964
	WO9922764
	US2004063911
	US2004132640
	US2004142856
	US2004072290
	US6602684
	US2003207346
	US4640835
	US4496689
	US4301144
	US4670417
	US4791192
	US4179337
	US4816397
	US5916771
	US5759808
	US6765087
	WO0114424
	WO9300431
	WO0032231
	US2004198680
	ZITVOGEL L. ET AL., IMMUNITY, vol. 39, no. l, 2013, pages 74 - 88
	VICARITRINCHIERI, IMMUNOL. REV., 2004
	LU, FRONTIERS IMMUNOL, 2014
	KIMCANTOR, CANCER IMMUNOL RES, vol. 2, 2014, pages 929 - 936
	HERBST ET AL., NATURE, vol. 515, 2014, pages 563 - 567
	KIMCANTOR, CANCER IMMUNOL. RES., vol. 2, 2014, pages 926 - 936
	KRIEG, NUCLEIC ACID THER., vol. 22, no. 2, 2012, pages 77 - 89
	KRUIT ET AL., J CLIN ONCOL, 2013
	TARHINI ET AL., J IMMUNOTHER, 2013
	LOVGREN ET AL., CANCER IMMUNOL IMMUNOTHER, 2012
	KARBACH ET AL., CLIN CANCER RES, 2011
	KARBACH ET AL., INT J CANCER, 2010
	SPEISER ET AL., JCI, 2005
	MANGSBO ET AL., J. IMMUNOTHER, vol. 33, 2010, pages 225
	RAJASAGI ET AL., BLOOD, vol. 124, no. 3, 2014, pages 453 - 462
	PRASANNA ET AL., J THORACIC DIS., vol. 6, no. 4, 2014, pages 287 - 302
	POSTOW ET AL., N. ENGL. J. MED., vol. 366, no. 10, 2012, pages 925 - 31
	GRIMALDI ET AL., ONCOIMMUNOL., vol. 3, 2014, pages e28780
	BARNES ET AL., BIOTECH & BIOENGINEERING, vol. 73, 2001, pages 261 - 270
	AUSUBEL ET AL.: "Current Protocols in Molecular Biology", 2002, JOHN WILEY & SONS
	PEARSON, METHODS ENZYMOL., vol. 183, 1990, pages 63 - 98
	THORNTON ET AL., NATURE, vol. 354, 1991, pages 105
	PEARSON, METHODS MOL. BIOL., vol. 243, 1994, pages 307 - 31
	GONNET ET AL., SCIENCE, vol. 256, 1992, pages 1443 - 45
	"Proteins, Structures and Molecular Principles", 1984, W. H. FREEMAN AND COMPANY
	PEARSON, METHODS MOL. BIOL., vol. 132, 2000, pages 185 - 219
	ALTSCHUL ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 - 410
	ALTSCHUL ET AL., NUCLEIC ACIDS RES., vol. 25, 1997, pages 3389 - 402
	CHOTHIA ET AL., NATURE, vol. 341, 1989, pages 544 - 546
	CHOTHIALESK, J. MOL. BIOL., vol. 196, 1987, pages 901 - 917
	BIRD ET AL., SCIENCE, vol. 242, 1988, pages 423 - 426
	HUSTON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 5879 - 5883
	ZEILDER, J. IMMUNOL., vol. 163, 1999, pages 1246 - 1252
	SOMASUNDARAM, HUM. ANTIBODIES, vol. 9, 1999, pages 47 - 54
	KELER, CANCER RES., vol. 57, 1997, pages 4008 - 4014
	HOLLIGER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 6444 - 6448
	POLLAK ET AL., STRUCTURE, vol. 2, 1994, pages 1121 - 1123
	KRIEG ET AL., J. IMMUNOTHER., vol. 27, 2004, pages 460 - 471
	TAUBE ET AL., CLIN CANCER RES., 2014
	SIEGAL ET AL., SCIENCE, 1999
	HARTMANN ET AL., EUR. J. IMMUNOL., vol. 33, 2003, pages 1633 - 1641
	MARSHALL ET AL., J. LEUKOCYTE BIOL., vol. 73, 2003, pages 781 - 792
	VOLLMER ET AL., EUR. J. IMMUNOL., vol. 34, 2004, pages 251 - 262
	MOSEMAN ET AL., J. IMMUNOL., vol. 173, no. 7, 2004, pages 4433 - 4442
	CHEN ET AL., J. IMMUNOL., vol. 181, no. 8, 2008, pages 5396 - 5404
	MOLENKAMP BG ET AL., CLIN CANCER RES., vol. 13, no. 10, 2007, pages 2961 - 2969
	MUMMOFT, BIOESSAYS, vol. 35, no. 7, 2013, pages 623 - 631
	SATO ET AL., IMMUNOL RES., vol. 51, no. 2-3, 2011, pages 170 - 182
	UHLMANN E ET AL., CHEM REV, vol. 90, 1990, pages 543
	GOODCHILD J, BIOCONJUGATE CHEM, vol. 1, 1990, pages 165
	SELIGER, H. ET AL.: "Oligonucleotide analogs with terminal 3'-3'- and 5'-5'-internucleotidic linkages as antisense inhibitors of viral gene expression", NUCLEOSIDES & NUCLEOTIDES, vol. 10, no. 1-3, 1991, pages 469 - 77
	M. D. MATTEUCCIM. H. CARUTHERS, TETRAHEDRON LETT., vol. 21, 1980, pages 719
	R. P. IYERW. EGANJ. B. REGANS. L. BEAUCAGE, J. AM. CHEM. SOC., vol. 112, 1990, pages 1253
	SERGUEEV, JAM CHEM SOC, vol. 120, 1998, pages 9417 - 27
	KRIEG ET AL., OLIGONUCLEOTIDES, vol. 13, no. 6, 2003, pages 491 - 499
	"Synthesis and Properties & Synthesis and Analytical Techniques", 1993, HUMANA PRESS, article "Protocols for Oligonucleotides and Analogs"
	CROOKE S T ET AL., ANNU REV PHARMACOL TOXICOL, vol. 36, 1996, pages 107 - 129
	HUNZIKER J ET AL., MOD SYNTH METHODS, vol. 7, 1995, pages 331 - 417
	UHLMANN EPEYMAN A: "Protocols for Oligonucleotides and Analogs", vol. 20, 1993, HUMANA PRESS, article "Methods in Molecular Biology", pages: 355 ff
	STIRCHAK E P ET AL., OLIGONUCLEOTIDES RES, vol. 17, 1989, pages 6129 - 41
	NIELSEN P E ET AL., BIOCONJUG CHEM, vol. 5, 1994, pages 3 - 7
	FROEHLER J, JAM CHEM SOC, vol. 114, 1992, pages 8320
	VANDENDRIESSCHE ET AL., TETRAHEDRON, vol. 49, 1993, pages 7223
	TARKOV M ET AL., HELV CHIMACTA, vol. 76, 1993, pages 481
	JIANG ET AL.: "Pseudo-cyclic oligonucleotides: in vitro and in vivo properties", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 7, no. 12, 1999, pages 2727 - 2735, XP085050417, DOI: 10.1016/S0968-0896(99)00217-5 DOI: http://dx.doi.org/10.1016/S0968-0896(99)00217-5
	DURAND, M. ET AL.: "Triple-helix formation by an oligonucleotide containing one (dA) and two (dT) sequences bridged by two hexaethylene glycol chains", BIOCHEMISTRY, vol. 31, no. 38, 1992, pages 9197 - 204, XP002329296, DOI: 10.1021/bi00153a012 DOI: http://dx.doi.org/10.1021/bi00153a012
	FONTANEL, MARIE LAURENCE ET AL.: "Sterical recognition by T4 polynucleotide kinase of non-nucleosidic moieties 5'-attached to oligonucleotides", OLIGONUCLEOTIDES RESEARCH, vol. 22, no. 11, 1994, pages 2022 - 7, XP002098767
	SCHMIDT M ET AL., ALLERGY, vol. 61, 2006, pages 56 - 63
	KAPP, K ET AL., MOL THER NUCLEIC ACIDS, vol. 3, 2014, pages e170
	RAMALHO ORTIGAO ET AL., ANTISENSE RESEARCH AND DEVELOPMENT, vol. 2, 1992, pages 129 - 46
	"GenBank", Database accession no. NP_001032720
	FRANSEN MF ET AL., ONCOIMMUNOLOGY, vol. 2, no. 11, 1 November 2013 (2013-11-01), pages e26493
	LONBERG ET AL., NATURE, vol. 368, 1994, pages 856 - 859
	TOMIZUKA ET AL., PROC NATL ACAD SCI USA, vol. 97, 2000, pages 722
	KUROIWA ET AL., NATURE BIOTECHNOL, vol. 18, 2000, pages 1086
	WINTERHARRIS, IMMUNOL. TODAY, vol. 14, 1993, pages 43 - 46
	WRIGHT ET AL., CRIT. REVIEWS IN IMMUNOL., vol. 12, 1992, pages 125 - 168
	THOTAKURA ET AL., METH. ENZYMOL., vol. 138, 1987, pages 350 - 97
	HAKIMUDDIN ET AL., ARCH. BIOCHEM. BIOPHYS., vol. 259, 1987, pages 52
	MILLWARD M. ET AL., BR. J. CANCER, vol. 108, no. 10, 2013, pages 1998 - 2004
	BRODY ET AL., J. CLIN. ONCOL., vol. 28, no. 28, 2010, pages 4324 - 4332
	KIM ET AL., BLOOD, vol. 119, no. 2, 2012, pages 355 - 363
	BURNETTE ET AL., CANCER RES., vol. 71, 2011, pages 2488 - 2496
	GOMES DOS SANTOS AL ET AL., CURR PHARM BIOTECHNOL., vol. 6, no. 1, 2005, pages 7 - 15
	JOSHI VB ET AL., AAPS J., vol. 15, no. 1, 2013, pages 85 - 94
	ARIMA H ET AL., CURR TOP MED CHEM., vol. 14, no. 4, 2014, pages 465 - 77
	"Sustained and Controlled Release Drug Delivery Systems", 1978, MARCEL DEKKER, INC.
	KRIEG AM ET AL., OLIGONUCLEOTIDE, vol. 13, no. 6, 2003, pages 491 - 9
	BEEH ET AL., J ALLERGY CLIN IMMUNOL, vol. 131, 2013, pages 866 - 74

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.